J van Ark-Otte

1.5k total citations
25 papers, 1.3k citations indexed

About

J van Ark-Otte is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, J van Ark-Otte has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in J van Ark-Otte's work include Cancer therapeutics and mechanisms (12 papers), Drug Transport and Resistance Mechanisms (7 papers) and Lung Cancer Research Studies (6 papers). J van Ark-Otte is often cited by papers focused on Cancer therapeutics and mechanisms (12 papers), Drug Transport and Resistance Mechanisms (7 papers) and Lung Cancer Research Studies (6 papers). J van Ark-Otte collaborates with scholars based in Netherlands, Italy and Spain. J van Ark-Otte's co-authors include Herbert M. Pinedo, Giuseppe Giaccone, Godefridus J. Peters, Benjamin Winograd, Paulo Eduardo Pizão, Paul van der Valk, Anne‐Marie C. Dingemans, Gonzalo Rubio, Pieter E. Postmus and Rik J. Scheper and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J van Ark-Otte

25 papers receiving 1.3k citations

Peers

J van Ark-Otte

MB

ONCOL

PRM

SURGE

OC

Donald J. Dykes United States

Axel‐R. Hanauske Germany

Yong‐ju Liang China

Tina Colombo Italy

Fumihiko Kanzawa United Kingdom

G G Chabot France

Hiroyuki Achiwa Japan

Chun-ling Dai China

A Wakui Japan

Lorraine A. Cazenave United States

Donald J. Dykes United States

J van Ark-Otte

681 ×0.9

MB

743 ×1.0

ONCOL

238 ×1.0

PRM

131 ×0.7

SURGE

123 ×0.7

OC

Citations per year, relative to J van Ark-Otte J van Ark-Otte (= 1×) peers Donald J. Dykes

Countries citing papers authored by J van Ark-Otte

Since Specialization

Citations

This map shows the geographic impact of J van Ark-Otte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J van Ark-Otte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J van Ark-Otte more than expected).

Fields of papers citing papers by J van Ark-Otte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J van Ark-Otte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J van Ark-Otte. The network helps show where J van Ark-Otte may publish in the future.

Co-authorship network of co-authors of J van Ark-Otte

This figure shows the co-authorship network connecting the top 25 collaborators of J van Ark-Otte. A scholar is included among the top collaborators of J van Ark-Otte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J van Ark-Otte. J van Ark-Otte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dingemans, Anne‐Marie C., J van Ark-Otte, Simone W. Span, et al.. (2001). Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer. 32(2). 117–128. 43 indexed citations

2.

Ark-Otte, J van, et al.. (1998). Determinants of CPT-11 and SN-38 activities in human lung cancer cells. British Journal of Cancer. 77(12). 2171–2176. 81 indexed citations

3.

Ark-Otte, J van, et al.. (1998). CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. British Journal of Cancer. 77(3). 359–365. 47 indexed citations

4.

Boven, Epie, HM Pinedo, P Scheffer, et al.. (1998). Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. British Journal of Cancer. 78(12). 1586–1593. 8 indexed citations

5.

Linn, Sabine C., Herbert M. Pinedo, J van Ark-Otte, et al.. (1997). Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International Journal of Cancer. 71(5). 787–795. 7 indexed citations

6.

Valk, Paul van der, J.S. de Jong, W. Devillé, et al.. (1997). Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.. Journal of Clinical Oncology. 15(6). 2456–2466. 137 indexed citations

7.

Linn, Sabine C., Herbert M. Pinedo, J van Ark-Otte, et al.. (1997). Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International Journal of Cancer. 71(5). 787–795. 84 indexed citations

8.

Ark-Otte, J van, et al.. (1997). Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. International Journal of Cancer. 73(6). 891–896. 33 indexed citations

9.

Giaccone, Giuseppe, J van Ark-Otte, Adi F. Gazdar, et al.. (1996). MRP is frequently expressed in human lung‐cancer cell lines, in non‐small‐cell lung cancer and in normal lung. International Journal of Cancer. 66(6). 760–767. 3 indexed citations

10.

Giaccone, Giuseppe, J van Ark-Otte, Adi F. Gazdar, et al.. (1996). MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. International Journal of Cancer. 66(6). 760–767. 51 indexed citations

11.

Dingemans, Anne‐Marie C., J van Ark-Otte, Paul van der Valk, et al.. (1996). Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Annals of Oncology. 7(6). 625–630. 42 indexed citations

12.

Pinedo, Herbert M., et al.. (1995). Effects of suramin on human lung cancer cell lines. European Journal of Cancer. 31(2). 244–251. 14 indexed citations

13.

Giaccone, Giuseppe, J van Ark-Otte, Giorgio V. Scagliotti, et al.. (1995). Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1264(3). 337–346. 64 indexed citations

14.

Pizão, Paulo Eduardo, et al.. (1994). Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochemical Pharmacology. 48(6). 1145–1154. 18 indexed citations

15.

Smitskamp-Wilms, Evelien, Godefridus J. Peters, Herbert M. Pinedo, J van Ark-Otte, & Giuseppe Giaccone. (1994). Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochemical Pharmacology. 47(8). 1325–1332. 34 indexed citations

16.

López-Reig, Raquel, Godefridus J. Peters, Evelien Smitskamp-Wilms, et al.. (1994). In vitro sequence-dependent synergistic effect of suramin and camptothecin. European Journal of Cancer. 30(11). 1670–1674. 3 indexed citations

17.

Peters, Godefridus J., R. Oskam, J van Ark-Otte, et al.. (1993). Transformation of mouse fibroblasts with the oncogenes H‐ras or trk is associated with pronounced changes in drug sensitivity and metabolism. International Journal of Cancer. 54(3). 450–455. 42 indexed citations

18.

Peters, Godefridus J., J van Ark-Otte, Lou A. Smets, et al.. (1993). Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. European Journal of Cancer. 29(11). 1566–1573. 34 indexed citations

19.

Lyaruu, D.M., Godefridus J. Peters, J van Ark-Otte, et al.. (1992). Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. British Journal of Cancer. 66(4). 660–665. 29 indexed citations

20.

Pizão, Paulo Eduardo, et al.. (1991). Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. European Journal of Cancer and Clinical Oncology. 27(7). 897–900. 405 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact